Site icon pharmaceutical daily

SECUADO® (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophrenia, is Now Available in the U.S.

MIAMI & JERSEY CITY, N.J.–(BUSINESS WIRE)–Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that SECUADO® (asenapine) transdermal system, the first-and-only transdermal patch formulation approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with schizophrenia, is now available by prescription in the U.S.1

SECUADO was approved by the FDA on October 15, 2019. The patch is applied every 24 hours and is available in three dosage strengths of asenapine: 3.8 mg/24 hour, 5.7 mg/24 hour and 7.6 mg/24 hour. The once-daily transdermal drug delivery system provides sustained concentrations during wear time (24 hours)2 of the atypical antipsychotic drug asenapine.

In the international, Phase 3, double-blind, placebo-controlled study, both doses of SECUADO included in the trial, 3.8 mg/24 hour and 7.6 mg/24 hour, achieved the primary endpoint, demonstrating statistically significant change from baseline to Week 6 in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo. Efficacy and safety were assessed during the six-week treatment period in 616 adults living with schizophrenia. Additionally, SECUADO demonstrated statistically significant improvement in Clinical Global Impression-Severity (CGI-S) scores, the key secondary endpoint in the Phase 3 study.

The most commonly observed adverse reactions were extrapyramidal disorder, application site reaction, and weight gain.1

Please click here for full Prescribing Information, including a Boxed Warning.

What is SECUADO?

SECUADO is a prescription medicine used to treat adults with schizophrenia. SECUADO is a transdermal system (patch) you apply to your skin. It is not known if SECUADO is safe and effective in children who are less than 18 years of age with schizophrenia.

IMPORTANT SAFETY INFORMATION

SECUADO may cause serious side effects, including:

Do not use SECUADO if you:

Before you use SECUADO, tell your healthcare provider about all of your medical conditions, including if you have or have had:

Tell your healthcare provider if you become pregnant or think you are pregnant during treatment with SECUADO. It is not known if SECUADO will harm your unborn baby.

Talk to your healthcare provider about the best way to feed your baby during treatment with SECUADO. It is not known if SECUADO passes into your breast milk.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. SECUADO and other medicines may affect each other causing possible serious side effects. SECUADO may affect the way other medicines work, and other medicines may affect how SECUADO works.

The most common side effects of SECUADO include:

Tell your healthcare provider if you have any side effects that bothers you or does not go away. These are not all the possible side effects of SECUADO.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

About Schizophrenia

Schizophrenia is a severe, chronic psychiatric disease with a heterogeneous course and symptom profile. The symptoms associated with schizophrenia are disabling and lifelong, and greatly affect a patient’s quality of life and social functioning. Symptoms usually start between ages 16 and 30 and fall into three categories: positive, negative and cognitive. Positive symptoms are psychotic behaviors not generally seen in healthy people and can include hallucinations, delusions, thought disorders and movement disorders. Negative symptoms are associated with disruptions to normal emotions and behaviors and can include flat affect (reduced expression of emotions), reduced feelings of pleasure in everyday life, difficulty beginning and sustaining activities and reduced speaking. Cognitive symptoms can include poor executive functioning (the ability to understand information and use it to make decisions), trouble focusing or paying attention and problems with working memory (the ability to use information immediately after learning it).3

About the Noven Care Access Network

The Noven Care Access Network (Noven C.A.N.) is designed to provide people living with schizophrenia and their caregivers SECUADO information and resources, including access to a support specialist. Additional information can be found at SECUADO.com.

About Noven

Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products. Noven’s mission is to develop and offer pharmaceutical products that meaningfully benefit patients around the world, with a commitment to advancing patient care through transdermal drug delivery. Noven is a stand-alone operating subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., serving as Hisamitsu’s U.S. platform for prescription pharmaceuticals, and helping Hisamitsu bring the benefits of patch therapy to the world. For more information about Noven, visit http://www.noven.com/. For information about Hisamitsu, visit https://global.hisamitsu/.

_____________________

1
SECUADO [prescribing information]. Miami, FL: Noven Therapeutics LLC; 2019.

2 Citrome, L, Zeni CM, Correll CU. Patches: Established and Emerging Transdermal treatments in psychiatry. J Clin Psychiatry 2019;90(4):18nr12554.

3 National Institute of Mental Health. Schizophrenia. [Internet]. Available from: https://www.nimh.nih.gov/health/statistics/schizophrenia.shtml
SECUADO® is a registered trademark of Hisamitsu Pharmaceutical Co., Inc.

© 2020 Noven Therapeutics, LLC. All rights reserved. For US audience only.

Contacts

Monica Lara

Noven Pharmaceuticals, Inc.

305-253-1916

Exit mobile version